AI
Thursday, November 10, 2022 12:20:38 AM
Thank you for highlighting the NIH.
NIH deserves to be highlighted and recognized for their part in the development of DCVax. Aside from the Nobel Prize-winning discovery of the dendritic cell and the brilliant work of Dr. Liau, NIH may be the single greatest factor that led to the development of the DCVax platform technology as a novel cell-based immunotherapy.
Here are some recent links to NIH news with regard to DCVax:
https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/
https://newsroom.ucla.edu/releases/nih-grant-lab-gene-cell-therapies
NIH NCI is largely responsible for the development of the DCVax platform technology as they have always supported and funded Liau’s work. The 20 consecutive years of NIH funding of Dr. Liau have played a direct and crucial role in DCVax. Together with Merck, NIH is funding the DCVax doses going into arms TODAY in a study investigating its efficacy in combo with Keytruda.
September 14, 2022 Update of NIH NCI Funding of Dr. Liau
https://connect.uclahealth.org/2022/09/14/brain-cancer-discovery-clinical-trials/
https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter
https://www.bentley.edu/news/nih-funded-research-related-every-new-cancer-drug-approved-2010-2016
9/14/2022
In a trial now underway, a dendritic cell vaccine is made from a participant's own tumor tissue and combined with an anti-PD1 immune checkpoint inhibitor to counter resistance when either treatment is used alone. The checkpoint drugs work by blocking the proteins that stop the immune system from attacking cancer cells.
"What I'm excited about is that we're seeing a growing number of long-term survivors in our patients treated with immunotherapy combinations," Dr. Liau says. "We're seeing some patients with certain combination immunotherapies that are living for many more years than would be expected. Currently, we're trying to find out what combination works best and for which patients."
The FDA and NIH work very closely together. Highly reputable licensed professionals have vetted the immunotherapy research of Dr. Liau, I would recommend that you research and study for yourself the recent 590 million dollar grant that was awarded to UCLA. The U.S. government NIH grant is funded by tax dollars and is public record for anyone who wants to see it. Many independent physicians have reviewed the immunotherapy work of Dr. Liau.
The NIH peer-reviewed grant is the source of funding being used today to dose patients with DCVax-L and Keytruda.
Department of Neurosurgery Chair Linda M. Liau, MD, PhD, MBA, was a leading recipient of NIH grants – No. 3 in the nation within the discipline.
“It's the stamp of approval from the NIH, because these types of grants are so rigorously peer-reviewed,” Dr. Liau says. “People get funded based on the strength of the science and that, itself, is very powerful in terms of showing that our research is scientifically valid and meaningful and hopefully will lead to future treatments.”
https://cancer.ucla.edu/research/ucla-brain-spore
NIH deserves to be highlighted and recognized for their part in the development of DCVax. Aside from the Nobel Prize-winning discovery of the dendritic cell and the brilliant work of Dr. Liau, NIH may be the single greatest factor that led to the development of the DCVax platform technology as a novel cell-based immunotherapy.
Here are some recent links to NIH news with regard to DCVax:
https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/
https://newsroom.ucla.edu/releases/nih-grant-lab-gene-cell-therapies
NIH NCI is largely responsible for the development of the DCVax platform technology as they have always supported and funded Liau’s work. The 20 consecutive years of NIH funding of Dr. Liau have played a direct and crucial role in DCVax. Together with Merck, NIH is funding the DCVax doses going into arms TODAY in a study investigating its efficacy in combo with Keytruda.
September 14, 2022 Update of NIH NCI Funding of Dr. Liau
https://connect.uclahealth.org/2022/09/14/brain-cancer-discovery-clinical-trials/
https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter
https://www.bentley.edu/news/nih-funded-research-related-every-new-cancer-drug-approved-2010-2016
9/14/2022
In a trial now underway, a dendritic cell vaccine is made from a participant's own tumor tissue and combined with an anti-PD1 immune checkpoint inhibitor to counter resistance when either treatment is used alone. The checkpoint drugs work by blocking the proteins that stop the immune system from attacking cancer cells.
"What I'm excited about is that we're seeing a growing number of long-term survivors in our patients treated with immunotherapy combinations," Dr. Liau says. "We're seeing some patients with certain combination immunotherapies that are living for many more years than would be expected. Currently, we're trying to find out what combination works best and for which patients."
The FDA and NIH work very closely together. Highly reputable licensed professionals have vetted the immunotherapy research of Dr. Liau, I would recommend that you research and study for yourself the recent 590 million dollar grant that was awarded to UCLA. The U.S. government NIH grant is funded by tax dollars and is public record for anyone who wants to see it. Many independent physicians have reviewed the immunotherapy work of Dr. Liau.
The NIH peer-reviewed grant is the source of funding being used today to dose patients with DCVax-L and Keytruda.
Department of Neurosurgery Chair Linda M. Liau, MD, PhD, MBA, was a leading recipient of NIH grants – No. 3 in the nation within the discipline.
“It's the stamp of approval from the NIH, because these types of grants are so rigorously peer-reviewed,” Dr. Liau says. “People get funded based on the strength of the science and that, itself, is very powerful in terms of showing that our research is scientifically valid and meaningful and hopefully will lead to future treatments.”
https://cancer.ucla.edu/research/ucla-brain-spore
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
